Clinical Trial Update: Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial of intratumoral gene-mediated cytotoxic immunotherapy for resectable non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• GMCTI (gene-mediated cytotoxic immunotherapy)

Snippet

Sponsor: Candel Therapeutics, Inc. | Conditions: Lung Cancer | Phase 1 | Status: COMPLETED